CN1676142A - Aloe wound-surface cleaning liquid, and its preparing method and use - Google Patents
Aloe wound-surface cleaning liquid, and its preparing method and use Download PDFInfo
- Publication number
- CN1676142A CN1676142A CN 200410017393 CN200410017393A CN1676142A CN 1676142 A CN1676142 A CN 1676142A CN 200410017393 CN200410017393 CN 200410017393 CN 200410017393 A CN200410017393 A CN 200410017393A CN 1676142 A CN1676142 A CN 1676142A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- wound
- borate buffer
- aloe
- molar concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention relates to a medicinal composite for cleaning surface of wound. Said medicinal composite mainly contains 10-60% (W/V) of aloe leaf flesh colloidal solution as main component, 0.01-0.2% (W/V) of benzalkonium bromide and boric acid buffer solution with 0.05-0.5 molar concentration, and the rest is excipient.
Description
Technical field
The present invention relates to contain the aloetic Pharmaceutical composition that surface wound cleans that is applied to, and its production and application.
Technical background
Wound surface is clinical common and influence the body appearance damage of work and quality of life.Wound surface is meant that human body organizes the damage of certain area at skin that made by various wounds, infection or other illness to take place behind some position pressurized ischemia etc.Wound surface destroys the natural cover for defense of body to external environment, large tracts of land degree of depth wound surface such as deep burn wound not only make the body fluid of rich in proteins and moisture continue to lose from wound surface, but and the wound surface slough cause fatal systemic infection take place in bacterial colonisation breeding and then the intrusive body.For keeping the stable of organismic internal environment, the shielding microorganism is to the infringement of body, and the clinical opinion of contemporary medical science is also rebuild the body barrier to the wound surface debridement as early as possible to remove the wound surface slough.
The present invention selects Aloe for use, and preparation is applied to the Pharmaceutical composition that clinical wound surface cleans as key component.Aloe is traditional medical material of motherland's medical science, and in the world, Aloe is to therapeutical effect just existing report since the eighties of wound surface.The research of Rodrignez-Bigas and Visuthikosold etc. shows that all the wound surface epithelization of employing Aloe treatment early.But China mostly is limited to cosmetic field or is applied to the trial of wound repair in the application facet of Aloe external, and the application aspect the wound surface cleaning is rarely in report.The present technique field is needed badly and is adopted advanced Pharmaceutical composition, effectively various surface wounds are cleared up.
Beneficial effect
The present invention has broken the technical monopoly of imported product in this field, filled up domestic blank, the development of product of the present invention helps the raising of the whole research and development technology of national natural plants, and can provide novel effectively product and method for clinical wound surface cleaning.
Summary of the invention
An object of the present invention is to provide novel, be the Pharmaceutical composition that surface wound cleans that is applied to of key component with the Aloe.
A further object of the present invention provides the preparation method of described Pharmaceutical composition.
Another object of the present invention provide described Pharmaceutical composition preparation to burn, the application of the medicine of various surface wound disease row debridements such as ulcer, surgical wound.
The objective of the invention is to implement: a kind of Pharmaceutical composition by following method, it is by the Aloe mesophyll colloid liquid of 10-60% (W/V), the benzalkonium bromide (bromogeramine) of 0.01-0.2% (W/V), the borate buffer of 0.05-0.5 molar concentration and the excipient of surplus are formed.
Described Pharmaceutical composition is a liquid form.PH value is 6.5-7.5.
Embodiment
Below in conjunction with specific embodiment the present invention is done further elaboration.
Embodiment 1:
Preparation contains 35% (W/V) Aloe mesophyll colloid liquid, 0.05% (W/V) benzalkonium bromide (bromogeramine); 0.1 the described Pharmaceutical composition of molar concentration borate buffer.
Take by weighing 2.94g boric acid and 0.24g Borax, be dissolved in the 50mL sterile distilled water.Obtain the borate buffer of 1.0 molar concentration, standby.
Measure commercially available 1: 1 Aloe mesophyll colloid liquid of 175mL, add commercially available 5% benzalkonium bromide (bromogeramine) solution 5mL, add the above-mentioned borate buffer of having prepared after the even matter, add water to 500mL, obtain colourless little turbid liquid.
Embodiment 2:
Preparation contains 30% (W/V) Aloe mesophyll colloid liquid, 3.0% (W/V) gentamycin,
0.05 the described Pharmaceutical composition of molar concentration borate buffer.
Take by weighing 1.47g boric acid and 0.12g Borax, be dissolved in the 50mL sterile distilled water.Obtain the borate buffer of 0.5 molar concentration, standby.
Measure commercially available 1: 1 Aloe mesophyll colloid liquid of 150mL, add commercially available 80,000 IU gentamicin sulfate solution 15mL, add the above-mentioned borate buffer of having prepared after the even matter, add water to 500mL, obtain colourless little turbid liquid.
Embodiment 3:
Preparation contains 50% (W/V) Aloe mesophyll colloid liquid, 0.05% (W/V) hibitane, the described Pharmaceutical composition of 0.1 molar concentration borate buffer.
Take by weighing 2.94g boric acid and 0.24g Borax, be dissolved in the 50mL sterile distilled water.Obtain the borate buffer of 1.0 molar concentration, standby.
Measure commercially available 1: 1 Aloe mesophyll colloid liquid of 250mL, add commercially available hibitane stock solution 0.25mL, add the above-mentioned borate buffer of having prepared after the even matter, add water to 500mL, obtain colourless little turbid liquid.
Embodiment 4:
Preparation contains 20% (W/V) Aloe mesophyll colloid liquid, 2.0% (W/V) acetic acid, the described Pharmaceutical composition of 0.15 molar concentration borate buffer.
Take by weighing 4.41g boric acid and 0.36g Borax, be dissolved in the 50mL sterile distilled water.Obtain the borate buffer of 1.50 molar concentration, standby.
Measure commercially available 1: 1 Aloe mesophyll colloid liquid of 100mL, add acetic acid 10mL, add the above-mentioned borate buffer of having prepared after the even matter, add water to 500mL, obtain colourless little turbid liquid.With NaOH adjust pH to 7.2.
Embodiment 5:
Preparation contains 60% (W/V) Aloe mesophyll colloid liquid, 1.0% (W/V) polygynax, the described Pharmaceutical composition of 0.3 molar concentration borate buffer.
Take by weighing 8.82g boric acid and 0.72g Borax, be dissolved in the 50mL sterile distilled water.Obtain the borate buffer of 3.0 molar concentration, standby.
Measure commercially available 1: 1 Aloe mesophyll colloid liquid of 300mL, add commercial sulfuric acid neomycin dry powder 5g, add the above-mentioned borate buffer of having prepared after the even matter, add water to 500mL, obtain colourless little turbid liquid.
Embodiment 6:
Preparation contains 10% (W/V) Aloe mesophyll colloid liquid, 0.02% (W/V) nitrofural, the described Pharmaceutical composition of 0.5 molar concentration borate buffer.
Take by weighing 14.70g boric acid and 1.20g Borax, be dissolved in the 50mL sterile distilled water.Obtain the borate buffer of 5.0 molar concentration, standby.
Measure commercially available 1: 1 Aloe mesophyll colloid liquid of 50mL, add commercially available nitrofural dry powder 0.1g, add the above-mentioned borate buffer of having prepared after the even matter, add water to 500mL, obtain colourless little turbid liquid.
Claims (4)
1. one kind is applied to the Pharmaceutical composition that wound surface cleans, and it is by the Aloe mesophyll colloid liquid of 10-60% (W/V), the benzalkonium bromide (bromogeramine) of 0.01-0.2% (W/V), and the borate buffer of 0.05-0.5 molar concentration and the excipient of surplus are formed.
2. Pharmaceutical composition according to claim 1 prepares like this:
Measure the Aloe mesophyll colloid liquid of 10-60% (W/V);
The benzalkonium bromide (bromogeramine) that adds 0.01-0.2% (W/V), even matter;
The borate buffer that adds 0.05-0.5 molar concentration, even matter also adds the excipient of surplus; Obtain colourless little turbid liquid.
3. Pharmaceutical composition according to claim 1 is liquid form.PH value is 6.5-7.5.
As the described Pharmaceutical composition of the arbitrary claim of claim 1-3 preparation to burn, the application of the medicine of various surface wound disease row debridements such as ulcer, surgical wound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410017393 CN1676142A (en) | 2004-04-01 | 2004-04-01 | Aloe wound-surface cleaning liquid, and its preparing method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410017393 CN1676142A (en) | 2004-04-01 | 2004-04-01 | Aloe wound-surface cleaning liquid, and its preparing method and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1676142A true CN1676142A (en) | 2005-10-05 |
Family
ID=35048993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410017393 Pending CN1676142A (en) | 2004-04-01 | 2004-04-01 | Aloe wound-surface cleaning liquid, and its preparing method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1676142A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505490A (en) * | 2012-06-20 | 2014-01-15 | 比亚迪股份有限公司 | Wound cleaning liquid |
-
2004
- 2004-04-01 CN CN 200410017393 patent/CN1676142A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505490A (en) * | 2012-06-20 | 2014-01-15 | 比亚迪股份有限公司 | Wound cleaning liquid |
| CN103505490B (en) * | 2012-06-20 | 2016-04-27 | 比亚迪股份有限公司 | A kind of cleaning wound liquid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190192731A1 (en) | Methods of use of biomaterial and injectable implant containing biomaterial | |
| US6645948B2 (en) | Nutritional composition for the treatment of connective tissue | |
| KR102030508B1 (en) | Hyaluronic acid composition | |
| US6476005B1 (en) | Oral and injectable nutritional composition | |
| JP5627445B2 (en) | Ophthalmic composition for silicone hydrogel contact lens | |
| CN1771986A (en) | Orally taken joint function protectant | |
| CN1903171A (en) | Nanometer silver type external use antibiotic gel for female external use and its prepn. method | |
| CN1140266C (en) | Use of a mixture of a diol and an alpha-hydroxy acid for treatment of hyperkeratotic skin diseases | |
| Bhati et al. | Role of hyaluronic acid in periodontal therapy | |
| CN1676142A (en) | Aloe wound-surface cleaning liquid, and its preparing method and use | |
| RU2450816C2 (en) | Compositions of hyaluronic acid salt for epithelial damages | |
| JPH115744A (en) | Aqueous solution preparation for external use containing hyaluronic acid | |
| CN1965857A (en) | Eye drop of povidone iodine and preparation process thereof | |
| CN1803200A (en) | Antibiotic and deodorant agent for shoes and socks | |
| CN1263824C (en) | Bioactivity molding moisture modifier for desertification soil and prepn. method | |
| CN1416907A (en) | Medical collagen sponge and its prepn | |
| CN1977941A (en) | Method for preparing female lotion fromaloe and its use | |
| CN109260457B (en) | Hyaluronic acid-interleukin 10 compound, preparation method and application thereof | |
| CA3093373A1 (en) | N-acylated hyaluronic acid for hyperuricemia and gouty arthritis | |
| CN1376670A (en) | Arginine-ketoprofen with antalgic and inflammation relieving actions and its preparing process | |
| BR112020025302A2 (en) | INCREASE ANTIBACTERIAL ACTIONS OF A DEPSIPEPTIDIC ANTIBIOTIC USING SYNERGIC QUANTITIES OF BORIC ACID | |
| CN1084624C (en) | Food capable of improving liver function | |
| CA2446615C (en) | Nutritional composition for the treatment of connective tissue | |
| CN1772168A (en) | Compound sterilizing aloe emulsion and its prepn and application | |
| CN110755597B (en) | External pharmaceutical composition for preventing and treating rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhao Yingde Document name: Notice of publication of application for patent for invention |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |